$129
BioNTech
Performance
Dividends
1.1%
1W
1M
YTD
1Y
3Y
About
Our vision is to harness the power of the immune system to develop novel therapies based on groundbreaking R&D with cutting-edge technologies $BNTX
Twitter
Web
Share
23/36
Growth Score
15/36
Dividend Score
Valuation
PE Ratio
3.04
PS Ratio
1.69
RSI
-
0
PEG Ratio
0
3
PRG Ratio
0.02
PDG Ratio
0
Growth
3344%33834%0-8%0-50%
108%67623%-7%-60%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
66.32%
3
Gross Margin
74.72%
3
Current Ratio
5.37
Return on Assets
45.55%
Return on Equity
65.53%
Return on inv. Capital
75.12%
Dividend Growth
0%0%0%
2023
2024
2025*
2
*Estimated growth
Dividends
Yield
1.64%
Per Year
1x
Payout Ratio
4.69%
Institutional Holder
39.429.824248.219.081
2553338
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2021 18.98B
2018
2019
2020
2021
3
Net Income 2021 10.29B
2018
2019
2020
2021
3
Gross Profit 2021 15.12B
2018
2019
2020
2021
3
What will move the market
These are the numbers that will move the market, and the guidance that will move it as well.
$8.93
99.68% YoY
EPS
4.40B
22.00% YoY
Revenue
Current Quarter Analyst Estimates
$2.96
99.21% YoY
EPS
2.07B
68.20% YoY
Revenue
Next Quarter Analyst Estimates
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
10.10.2019
MaketCap
31.28B
Country
DE
CEO
Prof. Ugur Sahin M.D.
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Updated 01.07.2025